
- Telehealth Visits
- Insurance plan information

Carolyn S. Calfee, MD, MS
Internal Medicine- Telehealth Visits
- Insurance plan information



Carolyn S. Calfee, MD, MS
Internal Medicine- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Carolyn S. Calfee is a pulmonologist who cares for patients in UCSF's intensive care units.
Calfee's research focuses on the causes and treatment of acute respiratory distress syndrome (ARDS). Her projects include studying the biologic differences within ARDS and how to target those differences by personalizing treatment; the role of environmental exposure, including to cigarette smoke and air pollution, in susceptibility to lung injury; and novel treatments for ARDS. During the coronavirus pandemic, she led research at UCSF to investigate how the immune system responds to COVID and to test promising new treatments for COVID-19-associated ARDS.
Calfee earned her medical degree from the University of Pennsylvania Perelman School of Medicine. At UCSF, she completed a residency in internal medicine, serving as chief resident, followed by a fellowship in pulmonary and critical care medicine. She also earned a master of advanced study degree in clinical research at UCSF. She joined the UCSF faculty in 2007 and is a member of the UCSF Center for Tobacco Control Research and Education.
Education & training
Board certification
- Critical Care Medicine, American Board of Internal Medicine
- Pulmonary Disease, American Board of Internal Med/Pulmonary Disease
Fellowship
- UCSF Medical Center - OMAG
Residency
- Internal Medicine, UCSF Medical Center - OMAG
Internship
- Internal Medicine, UCSF Medical Center - OMAG
Degree
- MD, University of Pennsylvania School of Medicine
My expertise
Specialties
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.